Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 23 hours ago
🌐 বাংলায় দেখুন

Indications

Edema

Ranibizumab is used to treat patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and diabetic macular edema (DME). It is also used for diabetic retinopathy, meaning non proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), in patients with diabetic macular edema (DME), and for myopic choroidal neovascularization (mCNV).

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Ranibizumab binds to the receptor binding site of active forms of VEGF-A, and that includes VEGF110, the biologically active, cleaved form of the molecule. In models of ocular angiogenesis and vascular occlusion, VEGF-A has been shown to cause neovascularization and leakage. It is thought to contribute to the pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO.

When ranibizumab attaches to VEGF-A, VEGF-A can no longer interact with its receptors, VEGFR1 and VEGFR2, on the surface of endothelial cells. This reduces endothelial cell proliferation, vascular leakage and the formation of new blood vessels.

Pregnancy & Breastfeeding

No adequate and well-controlled studies of Ranibizumab have been done in pregnant women. There are also no data on whether ranibizumab passes into human milk, what effect it has on a breastfed infant, or whether it changes milk production or excretion.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose of Ranibizumab is 0.5 mg (0.05 mL of 10 mg/mL solution), given as an intravitreal injection once a month (approximately 28 days). Patients may also be treated with 3 monthly doses followed by less frequent dosing with regular assessment, although this is not as effective. In the 9 months after the three initial monthly doses, less frequent dosing with 4 to 5 doses on average is expected to maintain visual acuity, while monthly dosing may be expected to give an additional average gain of 1 to 2 letters. Patients should be assessed regularly. Another option, again not as effective, is one dose every 3 months after 4 monthly doses. Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average. Patients should be assessed regularly. Macular Edema Following Retinal Vein Occlusion (RVO) Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended as an intravitreal injection once a month (approximately 28 days). In Studies RVO-1 and RVO-2, patients received monthly injections of Ranibizumab for 6 months. Re-treatment was guided by optical coherence tomography and visual acuity criteria. Even so, patients who were not treated at Month 6 lost visual acuity on average at Month 7, while patients who were treated at Month 6 did not. Patients should be treated monthly. Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) The recommended dose is Ranibizumab 0.3 mg (0.05 mL of 6 mg/mL solution), given as an intravitreal injection once a month (approximately 28 days). Myopic Choroidal Neovascularization (mCNV) Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL Ranibizumab solution) is recommended as an intravitreal injection once a month (approximately 28 days) for up to 3 months at the start. Patients may be retreated if needed.